Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 14OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Dermatologic 1

Conditions

Noonan Syndrome 6 1Melanoma 1ALK-positive Non-small Cell Lung Cancer 1

Interventions

Cyclophosphamide 548pembrolizumab 385Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Has results × ceritinib × Clear all
NCT02513667 2023-02-03

Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma

University of Texas Southwestern Medical Center

Phase 2 Terminated
14 enrolled 12 charts
Thoracic

ALK-positive Non-small Cell Lung Cancer

NCT02587650 2020-01-27

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

University of California, San Francisco

Phase 2 Terminated
1 enrolled 7 charts
Dermatologic

Noonan Syndrome 6, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡